Biogen’s Vumerity Patent Suit Against Zydus Whittled to Validity

Biogen Inc. and Alkermes Plc’s lawsuit over Zydus Lifesciences Ltd.’s proposed generic version of Vumerity is down to the validity of three asserted patents after Zydus agreed its copy of the multiple sclerosis drug infringes.

Zydus’ generic diroximel fumarate, Vumerity’s active ingredient, infringes certain claims of US Patent Nos. 8,669,281, 9,090,558, and 10,080,733, unless the asserted claims are found to be invalid or unenforceable, according to a stipulation and order approved Thursday by Judge Gregory B. Williams in the US District Court for the District of Delaware.

• Biogen is the exclusive licensee of Alkermes’ patents, which cover ...